Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an asset purchase agreement signed by the companies in December 2024 for up ...

Mumbai--Intas Pharmaceuticals Ltd said on Monday it has filed a draft prospectus with the Indian capital market regulator for an initial share sale. The company plans to raise up to 4.25 billion ...

Indian drugmaker Intas Pharmaceuticals is reportedly readying a bid for Biogen’s (BIIB) biosimilars business that could value the unit at up to $1B. Read more here.

Intas Pharmaceuticals’ new warning letter from the U.S. FDA reads like a checklist of what not to do when the regulator pays a visit to your manufacturing facility. The FDA handed Intas a five ...

After treatment with gonadotropin, clomiphene, or letrozole, clinical pregnancies occurred in 35.5%, 28.3%, and 22.4% of cycles, and live birth in 32.2%, 23.3%, and 18.7%, respectively; pregnancy ...

Lies, shredded documents and a trashcan dowsed in acid: Intas Pharmaceuticals’ new write-up from the U.S. FDA is a textbook example of what not to do when investigators come knocking.

Intas Pharmaceuticals in India made a widely used cancer drug in the U.S. An inspection exposed problems — and the fragility of the U.S. generic-drug supply.

The drug letrozole, which suppresses estrogen production, cut the risk of breast cancer recurrence nearly in half for older women who had already taken the standard tamoxifen treatment ...

A letrozole pill once a week restored fertility in obese, infertile men and led to their partners giving birth to two full-term, healthy babies, according to a new study from Canada.

Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. New England Journal of Medicine , 2014; 371 (2): 119 DOI: 10.1056/NEJMoa1313517 Cite This Page : ...

Studies of the effects of letrozole on plasma lipids have had conflicting results. 33,34 We found a nonsignificant difference in the rate of cardiovascular events between the letrozole group (4.1 ...